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This review of the literature aims to study potential associations between high
consumption of milk and/or dairy products and prostate cancer (PC). Literature is scarce,
yet there is a direct relationship between mTORC1 activation and PC; several ingredients
in milk/dairy products, when in high concentrations, increase signaling of the mTORC1
pathway. However, there are no studies showing an unequivocal relationship between
milk products PC initiation and/or progression. Three different reviews were conducted
with articles published in the last 5 years: (M1) PC and intake of dairy products, taking
into account the possible mTORC1signaling mechanism; (M2) Intake of milk products
and incidence/promotion of PC; (M3) mTORC1 activation signaling pathway, levels of
IGF-1 and PC; (M4) mTORC pathway and dairy products. Of the 32 reviews identified,
only 21 met the inclusion criteria and were analyzed. There is little scientific evidence that
directly link the three factors: incidence/promotion of PC, intake of dairy products and
PC, and PC and increased mTORC1 signaling. Persistent hyper-activation of mTORC1 is
associated with PC promotion. The activity of exosomal mRNA in cellular communication
may lead to different impacts of different types of milk and whether or not mammalian
milks will have their own characteristics within each species. Based on this review of
the literature, it is possible to establish a relationship between the consumption of milk
products and the progression of PC; we also found a possible association with PC
initiation, hence it is likely that the intake of dairy products should be reduced or minimized
in mens’ diet.
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INTRODUCTION
Prostate cancer (PC) is the most common in both sexes combined and the second most common
cancer in males. This type of cancer will be diagnosed in one in each seven males (1). According to
GLOBOCAN (2), in 2012 and all over the world, 1,1 million men diagnosed with PC which resulted
in 307,000 deaths. This number corresponds to 15% of total cancers diagnosed in males and about
70% are registered inmost developed regions. The PC incidence varies in all the world; however, the
higher rates occur in Australia/New Zealand and North America (ASR 111,6 e 97,2 per 100,000).
Vasconcelos et al. Dairy Products and Prostate Cancer
The incidence rate in western countries is very high and it can
reach 80 to 100 cases per 100,000 persons per year. In Africa
(North and East) and Eastern Asia, the incidence is lower: 10 to
20 cases per 100,000 persons.
In Portugal, according to the Portuguese Association of
Urology, PC constitutes the second cause of death by cancer, right
behind lung cancer, but is also the most frequent cancer in males
above 50 years old. It is estimated an incidence of 82 cases per
100,000 inhabitants and a mortality rate of 33 per 100,000. PC
represents about 3.5% of death causes and more than 10% of
death by cancer.
PC incidence is higher in developed countries: There is a
positive relationship between SIR (Standard Incidence Rate) and
Development Index and its components, such as human life
expectancy at birth, years of compulsory education and gross
per capita income (3, 4). Another reason to justify this high
PC incidence in developed countries may be connected with
diagnosis improvement and the introduction of the routine
evaluation of the specific antigen of PC (PSA) and the prostate
biopsy, besides the population aging and the increase risk
factors (5).
Prostate Cancer and Milk/Diet
Western diet, rich in milk and dairy products, animal fat and
sugars, with high calcium contents, is also connected to the
risk growth of PC (6–8). Greater per capita milk consumption
are probably correlated with higher PC incidence and mortality
according World Cancer Research Foundation 2007 (9–13).
Milk consumption has always been associated to child
mortality reduction, increased fertility, increase of children’s
BMI and of adolescence growth (14–16). Milk, relevant
sources of proteins and other macromolecules provides various
nutrients and bioactive molecules to support their growth
and development (15). However, milk consumption only in
adolescence was associated to an increase of 3.2 times the risk
of advanced PC in the cohort population of 8894 Icelandic
men (13).
According to the conclusions of a 2016 meta-analysis pursued
by investigators from the Republic of China, the ingestion of
dairy products has no significant impact in the mortality risk
increase in all kind of cancers while a small daily ingestion
of dairy products can even reduce the risk based on a non-
linear module (17). However, the same study concludes fat milk
consumption by men may contribute significantly to the increase
of PC mortality risk. There is thus a direct relationship between
milk ingestion and increased PC mortality (17, 18).
According to some authors, the increase of 35 gr./per day of
milk proteins consumption was associated to a 32% increase of
PC risk (19). In some Cohort studies, results are less conclusive
regarding milk negative impact (20–22). According to Nacional
Cancer Institute (USA), more than 2.6 million people in USA are
PC survivors and they have potentially improved the prognosis
Abbreviations: PC, Prostate Cancer; mTORC1, Mammalian Target of Rapamycin
Complex; P13K, phosphatidylinositol 3-kinase; Akt, Proteins kinase; IGF 1,
Insulin-like Growth Factor; BCAAs, Branched chain amino acids; T2DM, Type
2 Diabetes Mellitus; Aas, Amino acids; BMI, Body Mass Index.
by adopting healthy lifestyle habits (23). Limit the consumption
of meat and dairy products, particularly high fat, is part of the
recommendations to reduce the risk of PC progression (24).
Importance of Androgen Receptor for
Prostate Cancer
Androgen receptor (AR) mediated signaling is required for the
proliferation of prostate cancer cells and is a critical receptor
for the development and progression of prostate (25). Prostate
cancer is dependent on androgen receptor signaling (25). The
high concentration of steroid hormones present in dairy products
may, very probably, be related to the effect these products
have on the initiation and promotion of prostate and breast
cancer. (26). Dairy products concentrate hormones as insulin-
like growth factor-1 (IGF-1). (27–29). In recent years, according
to epidemiological evidence, the risk of colon, pancreatic,
endometrial, breast, and prostate tumors is associated with
high IGF-1 levels (30) and increased IGF/IGF-1R signaling is
implicated in all stages of carcinoma progression (31, 32). On the
other hand, according to a recently published review article, the
scientific evidence points to the intake of milk and dairy products
that meets the recommended nutrients that protect against the
most prevalent chronic diseases, however, the evidence for PC
is inconsistent (33). The androgen receptors and the signaling
mechanism of rapamycin complex 1 (mTORC1) and PI3 kinase-
AKT may be key points in the PC. (34, 35) and its dysregulation
is common in many human cancers such as prostate, colon,
breast and thyroid (36). The objective of this review of the
literature is to evaluate a potential correlation between milk and
dairy consumption and the incidence and progression of prostate
cancer, given that:
- The signaling pathway of mTORC1 and P13 Kinase-AKT is a
cancer-promoting mechanism (33, 37–42).
- Signaling of mTOR complex1 can be activated by BCAAs
(leucine), Glutamine, Insulin, IGF-1, glucose, ATP (43–47).
- Milk provides nutrients that can activate mTORC signaling
pathways (48, 49).
MATERIALS AND METHODS
Information Sources and Keywords
A search was performed in the PubMed (US National Library
of Medicine) using the terms MeSH (Medical Subject Headings)
identified and corresponding to the following keywords: prostate
cancer, dairy products, milk, IGF, mTORC1.
The various searches were performed using only MeSH terms:
“Prostatic Neoplasms”[MeSH], “Dairy Products”[MeSH],
“Cultured Milk Products”[MeSH], “mTOR protein,
human” [Supplementary Concept], “Insulin-Like
Growth Factor I”[MeSH], “mechanistic target of
rapamycin complex 1” [Supplementary Concept], “TOR
Serine-Threonine Kinases”[MeSH].
The research was done according to the following research
criteria relating the factors as follows (Figure 1):
a- Relate the incidence of PC to the consumption of dairy
products taking into account the possible signaling
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FIGURE 1 | Relationship between various searches.
mechanism of mTORC1. Research M1- with “Prostatic
Neoplasms” (MeSH) AND (“Dairy Products” [MeSH]
OR “Cultured Milk Products” [MeSH]) AND (“MTOR
protein, human” [Supplementary Concept] OR “Multiprotein
Complexes”] OR “Insulin-Like Growth Factor I” [MeSH])
b- Relate the intake of dairy products with the incidence of
PC-ResearchM2—with “Prostatic Neoplasms” (MeSH) AND
(“Dairy Products”) OR “Cultured Milk Products” (MeSH).
c- Relate the possible mechanism of activation of the mTORC1
signaling pathway, IGF1 levels with the PC-Research M3
with (Insulin-Like Growth Factor I [MeSH] OR mtor protein
[MeSH Terms] OR mechanistic target of rapamycin complex
1 [Supplementary Concept] OR “TOR Serine-Threonine
Kinases” [MeSH]) AND (prostate cancer [MeSH Terms] OR
“Prostatic Neoplasms” [MeSH]).
d- Relate the mTORC mechanism to dairy products—Research
M4 with dairy products [MeSH Terms] OR “Cultured Milk
Products” [MeSH]) AND [“mtor protein [MeSH Terms]” OR
mechanistic target of rapamycin complex 1 [MeSH Terms])
OR “TOR Serine-Threonine Kinases” [MeSH]).
Eligibility and Exclusion Criteria
The research was elaborated according to the following eligibility
criteria: Inclusion of review articles and systematic reviews,
published in the last 5 years, that restricted research to the
human species, male adults, as a target population and also
delimiting the research Cancer awareness. All articles were
manually analyzed and eligible studies should show association
between consumption of dairy products, PC and mTORC1
and/or IGF. Those whose content, despite including MeSH
terms defined, deviated from the objective of this review of the
literature, because they were out of the subject or because they
were repeated. Eligible articles are included in this review of
the literature.
RESULTS
As a result of the various surveys, 32 articles were reviewed and
systematic reviews divided by the groups (Table 1). Research
M1- No review or systematic review with the research was
identified in the database using the MeSH terms that relate the
consumption of dairy products to PC and to the mechanism
of activation of the mTORC1 signaling pathway. Although the
search with MeSH terms does not present any publication,
it was found that doing a search (Kw) using the keywords
(mTORC1) and (prostate cancer) and (milk), and not the
MeSH terms, there is a review within the scope of the Work
that relates cow’s milk to mTOR signaling and promotion and
initiation of PC.
Research M2−9 articles were identified that relate the
consumption of dairy products to PC, of which 4 were
excluded because they were included in the exclusion criteria.
Of these 4 studies, 3 were excluded because they related dairy
consumption to other specific cancers and not to PC or cancer
in general (50–53).
Research M3—With the research, 16 reviews and systematic
reviews were identified that relate PC to mTORC1 and IGF
mechanisms. These subjects were excluded from the study by 6: 3
because they addressed the issue of PC radiation (59–64).
Research M4—With the research, 7 systematic reviews and
reviews were identified. In this research the filters “human
species, man and cancer” were not used because they did not
apply to the subject in question. We excluded 1 review article
general (75) for being out of topic.
DISCUSSION
Dairy Products and Prostate Cancer
(Research M2)
Of the 5 eligible studies, 1 shows no relationship between dairy
intake and cancer. It also concludes that dairy intake reduces
the risk of colorectal cancer and is silent about PC (54). The
remaining 2 studies associate Dairy Products consumption with
increased risk and PC incidence (55, 56). 2 studies conclude that
PC prevention strategies go through moderation in consumption
of food, meat and dairy products (57, 58).
The first publication analyzed (54) concludes that there was
no consistent association between the consumption of dairy
products and all specific or non-specific causes of mortality.
In this systematic review were identified 408 studies of which
excluded 384 by the analysis of the title and abstract not to
be included in the theme of the review and excluded another
12 studies after analysis of its content. Of the 13 remnants the
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TABLE 1 | Search Results (Kw–search with keywords and no MeSH terms).
Search criteria Number of
articles excluded
Excluded
references
Number of
articles included
Included
references
Research M1 PC to the consumption of dairy products taking into
account the possible signaling mechanism of mTORC1.
0 0
Research M2 Relate the intake of dairy products with the incidence of
PC.
4 (50–53) 5 (54–58)
Research M3 Relate the possible mechanism of activation of the
mTORC1 signaling pathway, with the PC.
6 (59–64) 10 (65–74)
Research M4 Relate the mTORC mechanism to dairy products. 1 (75) 6 (76–81)
TOTAL 11 21
Research Kw PC to the consumption of dairy products taking into
account the possible signaling mechanism of mTORC1.
0 1 (82)
majority did not show consistent evidence on the relationship
between mortality and milk consumption (54).
An in-vivo study with 2 laboratory guinea pigs showed
that the consumption of high doses of milk did not produce
PC progression in early stages of tumorigenesis. In addition,
the authors conclude that regular milk consumption should
not be considered detrimental for patients with early prostatic
tumors (83). However, another in vitro study shows that
milk can stimulate the growth of prostate cancer cells in
culture (84).
Another review and meta-analysis (56) concluded that
ingestion of high amounts of dairy products, milk, low-fat
milk, cheese, yogurt, and calcium from dairy rather than from
supplements or sources Non-dairy products, may increase the
overall risk of prostate cancer. This review identified 45 relevant
studies, excluding 13 studies per repetition, comparing only 3
types of dairy products, when the objective would be all types
of dairy, or for moving away from the theme. The authors
also concluded that the divergent results for different types of
dairy products and calcium sources studied suggest that other
components in dairy products, in addition to fat and calcium,
may be related to the increased risk of PC (56).
The high intake of dairy products was also associated with
PC with some consistency. However, the same review (55)
reports a meta-analysis with 4 cohort studies that shows that
there is no evidence between intake of calcium added to dairy
products and PC (85). In their conclusions, they are vague in
this regard, warning of the need for further studies to clarify
the mechanisms involved in carcinogenesis linked to these
products (55, 85).
Intake of calcium through consumption of dairy products and
not through calcium provided by non-dairy products, showed a
positive association with the overall risk of prostate cancer in the
studies (55, 84–88). However, there was a divergence in results
that may be related to other components in dairy products (65).
Furthermore, the hypothesis that calcium from dairy products
may increase PC risk, does not explain the non-increased risk
with ingestion of non-dairy calcium sources (19, 87). Calcium
intake is positively associated with aggressive PC while vitamin D
intake shows an inverse relationship, and this association varies
according to race and BMI (89).
In this review of the literature, 2 studies were also
analyzed that are related to PC prevention strategies and
both conclude that there is some evidence that moderate
food consumption, reduction of dairy intake, Asian or
Mediterranean diet may help prevent PC associated with
other factors such as healthy habits (57, 58). There is very
significant evidence supporting the association between the
Mediterranean diet and the reduction of PC risk and disease
progression (90, 91).
mTOR, mTORC1, IGF-1, and Prostate
Cancer (Research M3)
Six studies conclude that deregulation of mTOR pathway
signaling is present in most PC and shows evidence for
possible therapy in castration-resistant or hormone-resistant
PC with inhibitors of these pathways (66–71); 3 studies relate
circulating amounts of IGF with PC progression (72–74); 1
Study associates positively the metabolic syndrome/IGF and PC
incidence (65).
Deregulation of the mTOR signaling pathway is associated
with the promotion or progression of PC and evidence for
possible PC therapy resistant to castration or hormone-resistant
with inhibitors of these pathways(69, 71). Rapamycin was the first
mTOR inhibitor discovered and approved for the treatment of
cancer. Thus, inhibitors of these pathways may be therapeutic
alternatives for PC; However, most are unstable molecules that
exhibit toxic effects, and further studies are needed (67, 68, 71).
On the other hand, fisetin, a dietary flavonoid, may act as a
double inhibitor of the PI3K/AKt and mTORC pathways. It is
a significant finding that the activation or overexpression of
mTOR signaling is common in tumors with overexpression of
Pi3K/Akt (66).
MTOR inhibitors may be a promising therapy in PC
that is resistant to conventional hormone therapy (67). The
mTOR protein plays a crucial role in this signaling pathway
being responsible for the regulation of cell growth and
protein synthesis. Changes in this pathway are associated with
carcinogenesis, angiogenesis, tumor growth and metastasis,
and this deregulation is present in almost 100% of the
advanced PCs (69, 92). Preclinical studies demonstrate that
the PI3K/Akt/mtORC signaling pathway plays a key role in
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the progression of castration-resistant PC (68, 70). Recent
literature shows that mTORC1 controls the programming in
mRNA translation of the genes involved in the initiation and
metastasis of PC (93–95). Reviews also relate PC to circulating
IGF amounts. IGF, essential for physiological growth, may
also be implicated in numerous diseases, including cancers.
Anabolic signs of IGF-1 may promote the development of
tumors through the anti-apoptosis effect and by stimulation
of cell proliferation (96, 97). Modulators of this factor, such
as IGFBP-6, may be useful in modeling the amount of IGFII
(73). Preclinical studies in PC show that the segmentation of
IGF receptors may constitute a promising anti-tumor effect
(74). The association between obesity/insulin resistance and PC
progression and lethality may be mediated through the activation
of the GH/IGF1 axis (72). Therapies that inhibit this axis may
play a preventive role in the progression of the disease (74).
There is a direct correlation between the metabolic syndrome,
hyperinsulinemia and elevated levels of IGF and PC(65). A recent
meta-analysis of 12 studies found a slightly increased risk for PC
incidence (odds ratio 1.38, 95% CI 1.19–1.60) in subjects with
higher serum IGF-1 levels. The authors have some limitations,
since they only use a single blood collection per patient, the
titration was performed only by laboratory methods, and in some
patients the stage of disease progression was not known (98).
However, epidemiological studies also show that higher levels
of circulating IGF-1 within normal ranges are associated with
increased risk of developing tumors including PC, colorectal
and breast cancer (99). If we analyze the influence of increased
mTOR pathway signaling on PC promotion, there is a great
deal of clear information and even many revisions that show
that the path of therapy may be related to this mechanism.
In almost 100% of PC there is deregulation of this signaling
pathway (92).
Dairy Products and Increased TOR, PI3
Kinase-AKT Signaling (Research M4)
The 6 eligible publications reflect a positive association
between milk consumption and increased mTORC1 signaling.
Human milk contains 1.2 g/100ml of milk proteins compared
to cow’s milk containing 3.5 g/100ml, almost 3 times more
branched-chain amino acid proteins (BCAAs) (77, 79, 100–
102), especially leucine (103). The available BCAAs play
a key role in the activation of the mTORC1 complex
(104–106). Glutamine in milk, 70% more than in meat
(107) is also an amino acid with important activation
power of mTORC1 (108, 109). In addition, pasteurized cow’s
milk transfers biologically active exosomal microRNA to the
systemic circulation of the consumer that apparently can
affect more than 11,000 human genes, including the mTORC1
complex (80). Breast milk has an essential role in regulating
growth during the postnatal period of mammals (110) and
constitutes a complex bio-fluid that transfers nutritionally
important, protective and fundamental substances for the
optimal developme nt of the baby (62). However, their intake
during adolescence seems to be being called into question.
Excess nutrients from dairy products ingested systematically
since adolescence, such as glutamine, BCAAs, leucine, palmitic
acid, IGF, bioactive exosomal microRNAs promote an over-
activation of the mTORC1 complex with consequent increase
in transcription, translocation of mRNA, cell growth and
proliferation cellular (44, 105, 106, 111–113).
Milk may represent the most sophisticated endocrine
regulation system for the activation of mTORC1 complex (78) for
the supply of BCAAs from milk proteins and exosomal mRNA
produced by mammary glands that contribute to the activation
of mTORC1 related to Numerous modern diseases (114, 115).
Excessively ingested milk may be an epigenetic amplifier of
the FTO gene-mediated transcription (79). The FTO gene
(association and obesity and fat mass) is assigned a fundamental
role in the control of body weight, body composition and energy
balance (116). Milk, the most common food introduced from an
early age, is not only a food but also represents a sophisticated
signaling system that promotes mTORC-mediated growth (78)
and has also been shown to stimulate mTORc1-dependent
translocation (80). The increased expression of themilk-activated
FTO gene leads to mTOR deregulation and increased mRNA
translation (117). Individuals with this epigenetic alteration may
be more susceptible to milk-mediated FTO activation (79). In
addition, there is also a positive correlation between circulating
IGF-1 levels and milk consumption. After the meta-analysis,
the weighted mean difference in circulating IGF-I level was
13.8 ng/ml (95% confidence interval: 6.1–21.5 ng/ml) comparing
the intervention group with the control group (32). However,
factors such as insulin, IGF and isolated amino acids do not
appear to be sufficient for maximal activation of TORC1 (118).
On the other hand, insulin in the presence of amino acids from
dairy products can induce a maximal activation of mTORC1
(119). Other reviews analyzed, relate the consumption of dairy
products and the activation of the mTORC signaling pathway
and conclude that milk consumption during pregnancy can be
determinant in the risk of developing diseases of civilization,
such as obesity, diabetes, and cancer (76) and therefore the
limits of milk consumption during this phase should be
reevaluated (120).
The exaggerated increase in western dietary mTORC1
signaling may explain the association between diabetes mellitus
(81) and acne (121) with increased fat mass, insulin resistance
(122) and early menarche (15). They may also be indicators of
over-activation of themammalian target of rapamycin 1 complex,
arterial hypertension (38, 123–125).
Dairy, Prostate Cancer, and Increased
mTOR Signaling (Research KW)
No review was found with the selection criteria that directly
related the incidence of PC with increased signaling of the
mTORC pathway induced by dairy products. However, the
identified study where the keywords were used and not
the MeSH terms (Kw research), relates the impact of cow’s
milk on mTORC1 signaling on PC initiation and progression
(82). PC is dependent on androgen receptors and aberrations
in PI3K/Akt-mTORC1 pathways, by excessive signaling. This
activation enhances mRNA transcription and distinct phases of
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PC initiation and progression. Some components of cow’s milk,
not breast milk, can activate mTORC. Increased intakes of cow’s
milk, dairy proteins, and estrogens in cow’s milk, especially of
pregnant cows, may explain the high incidence of PC in modern
Western societies. Milk proteins contribute to the increase of
branched-chain amino acids (BCAAs—leucine, isoleucine, and
valine) and elevated postprandial plasma levels of IGF-1 insulin,
which activatemTORC-signaling pathways (82, 126, 127). Higher
levels of glucose and ATP may also be implicated in this
deregulation (44, 128). However, studies show evidence that only
whole milk may be associated with a high incidence of lethal
PC (129). The FTO gene is associated with increased PC risk
(130, 131). Milk-mediated epigenetic activation of FTO can lead
to FTO activation leading to the activation of mTORC1 (65)
and possibly related to the onset and metastasis of PC (82, 95).
Consumption of dairy products may increase this signaling, since
current milk is concentrated in the nutrients that contribute
to its over-activation. The activation of mTORC1 depends on
available amounts of AAs, specifically BCAAs and leucine,
glutamine, IGF, insulin, exosomal micro mRNA, palmitic acid,
high glucose levels, and ATP (44, 80, 128). However, it should
be clarified which type of dairy and what concentrations in
hormones, leucine, IgF, BCAAs required for mTORC activation
and synergistic combinations of potentiating nutrients (119).
The origin of milk (cow, goat, sheep, and pregnant cows), type
of dairy products and amounts of intake may imply different
impacts on the increased risk and progression of PC (132). The
studies analyzed do not differentiate this question. According to
the studies, the impact on risk may also be dependent on the
time at which dairy consumption is higher, and in the postnatal
period, the benefits of breast milk consumption are unequivocal,
whereas during adolescence the consumption of milk from cow
may contribute to the increased risk of PC (13). Exosomal mRNA
activity in cell communication may lead to different impacts of
different types of milk and whether or not mammalian milks
will have their own characteristics within each species. Can
the microRNAs contained in cow’s milk induce this change in
other mammals?
Some polymorphisms may also be decisive in PC expression,
such as FTO (65, 79). Is this increase in signaling dependent on
some other polymorphism?
Eligible studies in this research have some limitations.
The definition of search criteria is very extended, there was
substantial heterogeneity among studies of non-fermented
milk consumption in relation to mortality from all causes.
Nor have any reviews considered the different types of
dairy products, diverging results for types of dairy products
and sources of calcium suggest that other components
of dairy than fat and calcium may increase prostate
cancer risk.
Some authors conclude that moderate food consumption,
reduction of dairy products can prevent prostate cancer but also
harbors additional beneficial effects on general health. However,
moderate consumption and the kind of dairy Products are not
defined. No review correlates with other concomitant eating
habits, genetic factors, or lifestyle.
CONCLUSIONS
Studies reviews selected through defined research criteria that
directly relate to dairy consumption and PC are contradictory,
inconsistent, and omitted in possible justifications or responsible
mechanisms. Nevertheless, most of the reviews point to a positive
association between milk consumption and the incidence or
increase of PC risk. However, there is strong evidence in the
literature (not reviews) that associates dairy consumption and PC
(91) and disease progression (82, 133), and possibly initialization
(82). Through this review of the literature we understand the
different mechanisms triggered by nutrients contained in milk
and derivatives that may lead to an increased risk of prostate
cancer in its consumers. However, further studies are needed
to clarify which detrimental derivatives and which quantities
are required for tumor progression and/or initiation. A better
understanding of cancer and this signaling pathway may lead
to the development of more effective and tumor-specific drugs
and to define preventive measures of the tumor with a higher
incidence in man and other types of cancer, such as breast
cancer (67).
In conclusion, according to the analysis of the available
information, it is possible to establish a relationship between
the consumption of dairy products and the progression of PC
and possibly its initiation and should therefore be reduced or
minimized in the diet of men.
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